Clinical Trials

The NIH has awarded a **$2.25 million** SBIR grant to **Tempo Therapeutics** for a clinical trial on their MAP™ Wound Matrix technology. This funding underscores the federal commitment to support innovative biomedical solutions aimed at improving patient outcomes in wound care, creating potential avenues for contractors specializing in advanced medical device technology.

The FDA has launched an Expedited IND Pilot program to enhance clinical trial timelines through strategic partnerships. By facilitating collaboration between drug sponsors and research institutions, this initiative opens new contracting opportunities for firms in clinical support services, regulatory consulting, and related fields.

The HHS Office of Minority Health has launched a $3 million funding initiative for FY 2026 to enhance inclusion in lupus clinical trials among underrepresented populations. With awards of up to $500,000, organizations are invited to submit applications by July 10, 2026, emphasizing health equity and minority health outreach.

DARPA's RAPIID program intends to create synthetic blood substitutes for battlefield use, targeting FDA approval by FY2029. The program seeks proposals addressing blood component development and delivery technologies, presenting a robust opportunity landscape for companies in medical innovation and regulatory compliance.

The VA has launched a clinical trial for MDMA-assisted therapy, targeting PTSD and alcohol use disorder among Veterans. This initiative, in coordination with the FDA, presents procurement opportunities related to clinical research and mental health services.